Raynovent Announces Approval of Investigational New Drug (IND) Application of Category 1 Drug ZSP0678 for a New Indication
The China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application of Category 1 Drug ZSP0678 for a new indication, Primary Biliary Cholangitis (PBC).
Raynovent Was Invited to Attend Focusing on Innovation, Seeking Development - Innovation Forum of Pharmaceutical Enterprises under The New Situation.
Today, Guangdong Biopharmaceutical Innovation Technology Association Membership Conference 2019 and Innovation Forum for Pharmaceutical Enterprises under the New Situation was successfully held at the International Conference Center of Guangzhou Sunshine Hotel.
Raynovent Announces Signing of Strategic Cooperation Agreement with Raffles
Guangdong Zhongsheng Raynovent Biotechnology Co., Ltd has signed a strategic cooperation agreement with Guangdong Raffles Pharmaceutical Technology Co., Ltd and announced further in-depth cooperation in API process optimization, clinical sample preparation and new drugs commercial production.
Dr. Chen Xiaoxin, Vice President of Raynovent was Invited to Attend Shenzhen International Biopharmaceutical Industry Innovation & Development Summit 2019.
From September 11 to 12, 2019, Shenzhen International Biopharmaceutical Industry Innovation & Development Summit 2019 was successfully held at Shenzhen Yanzi Lake International Convention and Exhibition Center.